INSIGHTS ON UPSTREAM MANUFACTURING

• Addressing Gaps In The CGT Market Through Partnership

  Reducing variability is critical to advancing cell therapy development. Learn how cell sourcing, quality-focused manufacturing strategies, and ecosystem partnerships can support reproducible research.

• Future-Focused Customer-Centric Bioprocessing Solutions With Eppendorf

  De-risk bioprocess scale-up with application-focused workflow validation. Discover strategies for transitioning therapies from R&D to clinical production.

• Designing Scalable Cell Therapy For Successful Development

  Only 49 cell and gene therapies have reached approval despite 5,000+ active clinical trials. Closing that gap requires designing for commercial-scale manufacturing from the earliest research decisions.

• Enhancing AAV Manufacturing Yield Via Mini-Helper Plasmid

  Learn how rational plasmid engineering and promoter optimization can significantly improve AAV productivity while reducing plasmid burden, paving the way for more efficient and scalable viral vector manufacturing.

• Navigating AI Compliance In Life Sciences: FDA Policy Insights For AI Governance

  7/22/2026

  Navigating life sciences AI compliance requires strong governance, expert human oversight, and transparent, low-risk deployment strategies.

• Next-Generation Mesenchymal Stem Cells For Cancer And Regenerative Medicine

  7/21/2026

  Researchers are advancing engineered mesenchymal stem cells using efficient non-viral gene delivery, enabling scalable, targeted therapies for solid tumors while preserving tumor-homing function and manufacturability.

• Perfusion Cultivations With ExpiCHO-S Cells Using The Minifors 2 Bioreactor

  7/21/2026

  High-density perfusion cultivation can support stronger productivity in a smaller footprint. See how integrated cell retention and process control enabled rapid growth, high viable cell densities, and strong IgG titres in eight days.

• Human Derived Cell Substrate Characterization

  7/20/2026

  Safe human cell line use needs key safety, identity, and purity testing steps at each cell bank stage. Robust assay plans assure full regulatory compliance, high safety, and product quality.